#BioPER - Twitter Hashtag

almost 4 years ago

We're glad to announce final results for our #BioPER trial have been published in @CCR_AACR! This is the 1st prospective published study to evaluate the antitumor act., safety, & predictive biomarkers of CDK4/6 inhibitor rechallenge in HR+/HER2- ABC pts. https://t.co/u3wBeGOl26

1

9

3

0

Andrea Malfettone @AMalfettonePhD

almost 4 years ago

#BioPER trial explored #palbociclib maintenance after PD on the same CDK4/6i 32 pts with pretreated HR+HER2- #MBC ✅CBR 34.4% (2 PR, 9 SD) ✅mPFS 2.6 mo ✅Baseline ⬇️Rb/⬆️cyclin E1/ESR1m predict worse outcome (HR 22.0; P=0.018) 🧐Confirmatory #PALMIRA trial is ongoing @OncoAlert

AMalfettonePhD's tweet photo. #BioPER trial explored #palbociclib maintenance after PD on the same CDK4/6i
32 pts with pretreated HR+HER2- #MBC
✅CBR 34.4% (2 PR, 9 SD)
✅mPFS 2.6 mo
✅Baseline ⬇️Rb/⬆️cyclin E1/ESR1m predict worse outcome (HR 22.0; P=0.018)
🧐Confirmatory #PALMIRA trial is ongoing
@OncoAlert https://t.co/o6ILaVcf0z

0

3

0

Paolo Tarantino

@PTarantinoMD

almost 4 years ago

Interesting findings from #BioPER of palbo/ET rechallenge in pts deriving benefit from prior palbo. Despite patient selection, CBR was 34%, ORR 6%, PFS 2.6 mo. Of note, 37% of these tumors were HER2-E (effect of prior CDK?), with reduced clinical benefit. https://t.co/ULG2p0djbp

PTarantinoMD's tweet photo. Interesting findings from #BioPER of palbo/ET rechallenge in pts deriving benefit from prior palbo. Despite patient selection, CBR was 34%, ORR 6%, PFS 2.6 mo. Of note, 37% of these tumors were HER2-E (effect of prior CDK?), with reduced clinical benefit.
https://t.co/ULG2p0djbp https://t.co/80XO74THVl

0

56

16

2

0

MEDSIR @wearemedsir

almost 6 years ago

Last week at @SABCSSanAntonio results of the #BIOPER study were presented by Dr. Antonio Llombart Cussac. The poster presentation summarized the outcome of this multicenter, open-label, non-controlled phase II #clinicaltrial with metastatic #breastcancer patients. #SABCS20

wearemedsir's tweet photo. Last week at
@SABCSSanAntonio
results of the #BIOPER study were presented by Dr. Antonio Llombart Cussac.
The poster presentation summarized the outcome of this multicenter, open-label, non-controlled phase II #clinicaltrial with metastatic #breastcancer patients.
#SABCS20

0

5

3

0

MEDSIR @wearemedsir

almost 6 years ago

MEDSIR is proud take part in the @SABCSSanAntonio virtual conference where we will be presenting the results from breast cancer #PARSIFAL trial, lead by Dr JM Pérez García and breast cancer #BIOPER trial, lead by Dr Antonio Llombart ⠀⠀⠀⠀⠀⠀⠀ #SABCS20 #BreastCancer

wearemedsir's tweet photo. MEDSIR is proud take part in the @SABCSSanAntonio virtual conference where we will be presenting the results from breast cancer #PARSIFAL trial, lead by Dr JM Pérez García and breast cancer #BIOPER trial, lead by Dr Antonio Llombart
⠀⠀⠀⠀⠀⠀⠀
#SABCS20 #BreastCancer

0

4

2

0

Top Tweets for #BioPER

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users